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Abstract
 
The immune response to phosphocholine (PC)–protein is characterized by a shift in antibody
repertoire as the response progresses. This change in expressed gene combinations is accompa-
nied by a shift in fine specificity toward the carrier, resulting in high affinity to PC–protein.
The somatically mutated memory hybridoma, M3C65, possesses high affinity for PC–protein
and the phenyl-hapten analogue, 
 
p
 
-nitrophenyl phosphocholine (NPPC). Affinity measure-
ments using related PC–phenyl analogues, including peptides of varying lengths, demonstrate
that carrier determinants contribute to binding affinity and that somatic mutations alter this rec-
ognition. The crystal structure of an M3C65–NPPC complex at 2.35-Å resolution allows eval-
uation of the three light chain mutations that confer high-affinity binding to NPPC. Only one
of the mutations involves a contact residue, whereas the other two have indirect effects on the
shape of the combining site. Comparison of the M3C65 structure to that of T15, an antibody
dominating the primary response, provides clear structural evidence for the role of carrier de-
terminants in promoting repertoire shift. These two antibodies express unrelated variable re-
gion heavy and light chain genes and represent a classic example of the effect of repertoire shift
on maturation of the immune response.
Key words: immunoglobulin • somatic mutation • X-ray crystallography • antibody afﬁnity • 
afﬁnity maturation
 
Introduction
 
Affinity maturation of serum antibodies occurs during the
immune response to T cell–dependent antigens (1) and can
be critical for protective immunity. In many antibody re-
sponses, much of the diversity exhibited by secondary and
memory antibody populations is provided by somatic mu-
tation of primary gene combinations (2–5). However, an-
other level of diversity can also be provided by recruitment
of new germline VH and VL genes during the response,
termed repertoire shift (6). These new gene combinations
are frequently modified by mutation, providing high affin-
ity for the immunogen (4, 6–8). The molecular basis of this
selective process is not entirely clear, but may depend in
part on a shift in specificity toward recognition of the hap-
ten plus carrier determinants.
The antibody response to phosphocholine (PC)
 
1
 
 is bio-
logically interesting because of the frequent expression of
PC on pathogenic bacteria and nematodes where the hap-
tenic epitope is coupled to a variety of carrier structures,
including carbohydrates and proteins (9–11). The murine
response to PC–protein is a well-characterized model sys-
tem used to study the shift in specificity to include the car-
rier as the immune response progresses (7, 12–15). After
immunization with PC coupled to KLH via a diazophenyl
linker, the antibody population specific for PC at the onset
of the primary response (group I antibodies) shifts to one
that includes the carrier as part of a more complex epitope.
Thus the response matures, evolving toward a population
that has a strong requirement for PC in the context of the
nitrophenyl linker (group II antibodies). The emergent
group II antibody population requires recruitment and ex-
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pansion of B cell clones expressing novel V gene combina-
tions rarely seen in the primary response (7). The expan-
sion and eventual dominance by a minor component of the
initial antibody repertoire points to the importance of car-
rier determinants in selecting and stimulating lymphocytes
of the group II phenotype that predominate in the memory
pool.
We have shown previously that somatic mutation in a
prototype group II hybridoma, M3C65, results in a dramatic
increase in affinity for antigen. High affinity for 
 
p
 
-nitro-
phenyl phosphocholine (NPPC), a hapten that mimics the
diazophenyl linkage between PC and protein, is attribut-
able to mutations at three positions in CDR2 of the
M3C65 
 
l
 
1 L chain (16). Accumulation of replacement
mutations at these key positions in the L chain occurs re-
peatedly in B cells undergoing affinity maturation in re-
sponse to PC–KLH (17).
In this study, we use crystallographic and affinity analysis
to reveal the molecular basis for the repertoire shift that oc-
curs after immunization with PC–KLH. We determine the
intrinsic affinity of M3C65 in its mutated and germline
forms for compounds representing various portions of the
carrier protein coupled to PC. We also solved the crystal
structure of the single-chain Fv (sFv) of this antibody com-
plexed to NPPC. The M3C65 combining site has an un-
usual requirement for direct interaction of the LCDR2
with NPPC, a finding that is rare for binding of small hap-
ten molecules (18). The structure of the complex provides
a stereochemical basis for emergence of group II domi-
nance in a secondary response, and allows evaluation of the
direct and indirect effects of L chain modification by so-
matic mutation in generating high affinity in the M3C65
hybridoma.
 
Materials and Methods
 
Synthesis and Expression of M3C65 sFv. 
 
cDNA copies of the
VH and VL genes of the hybridoma M3C65 (16) were synthe-
sized from mRNA using random hexamer primers (Amersham
Pharmacia Biotech). PCR amplification was carried out using a
primer for the 5
 
9
 
 portion of V
 
l
 
1 (5
 
9
 
agatcgcatgccatggGACA-
GGCTGTTGTGACTCATGGAA-3
 
9
 
) and a primer for the 3
 
9
 
 por-
tion of J
 
l
 
1 plus the 5
 
9
 
 part of the (Gly
 
4
 
Ser)
 
3 
 
linker (5
 
9
 
-cggacccacc-
accgcccgagccaccgccaccACCTAGGACAGTCAGTTTGGT-3
 
9
 
).
Amplification of the VH M141/D/JH3 gene was carried out us-
ing a primer for the 3
 
9
 
 part of the linker plus the 5
 
9
 
VH (5
 
9
 
-tcg-
ggcggtggtgggtccggaggcggatctCAGGTGCAGCTGAAGGAGTC
AG-3
 
9
 
) and a primer for the 3
 
9
 
 end of JH3 plus two stop codons
and an NcoI site (5
 
9
 
-agatcgcatgccatggttatcaTGCAGAGACAGT-
GACCAGAGTCCC-3
 
9
 
). NcoI sites are underlined, and V re-
gion coding sequences are capitalized. The VL and VH genes
were joined by PCR with the linker (Gly
 
4
 
Ser)
 
3
 
 in the order
VL-linker-VH. The amplified sFv DNA was ligated into the
NcoI site of the pET3d vector (Novagen), sequenced, and trans-
formed into 
 
E
 
s
 
cherichia coli 
 
Bl21(DE3). DNA sequencing of
clone 2-1.2 showed that the deduced protein sequence was
identical to the M3C65 hybridoma. The induced protein sFv
inclusions (24.9 kD) were denatured and refolded as described
(19). Renatured sFv fragments were purified by affinity chro-
matography on PC–sepharose as described for intact antibody
(12).
 
Transfectant Antibodies and K
 
a
 
 Determination. 
 
Antibodies ex-
pressing mutations at 
 
l
 
 L chain positions 52, 53, or 55 produced
by site-directed mutagenesis and the method for determination of
binding constants by fluorescence quenching have been described
(16). Stable transfectants cotransfected with the M3C65 H chain
and the various mutant L chain constructs were made in the SP2/0
cell line and purified as described previously (16). The synthesis
and structure of monoconjugates of PC coupled to tyrosine, histi-
dine, and the Gly-Tyr-Ala tripeptide have been described; PC is
coupled to Tyr on the tripeptide (20). These compounds were
provided by Drs. D. Peyton, E. Barbar, and H. Moulton (Port-
land State University, Portland, OR). A 15–amino acid peptide,
acetylated at the NH
 
2
 
 terminus (Peptide Express), was designed
to contain one haptenation site and to have 
 
a
 
-helical secondary
structure (21). The peptide, Ser-Asp-Ala-Leu-Ala-Glu-Met-Tyr-
Glu-Leu-Met-Ala-Val-Asp-Gly, was coupled to PC at the Tyr
residue as described previously (22). PC–histone was coupled by
the same method and has a PC/protein ratio of 2:1.
 
Crystallization of M3C65 sFv Complexed to NPPC. 
 
The pu-
rified sFv at 400 
 
m
 
g/ml was dialyzed against 20 mM Tris, pH 7.6,
concentrated to 5.6 mg/ml, and NPPC was added to a final con-
centration of 2 mM. Crystals were grown at room temperature
by vapor diffusion from a reservoir buffer that contained 1.5 M
NaH
 
2
 
PO
 
4
 
/K
 
2
 
HPO
 
4
 
, pH 6.5, and 0.1 M Hepes buffer (GIBCO
BRL). The crystals are orthorhombic, take the space group
P2
 
1
 
2
 
1
 
2
 
1 
 
(a 
 
5 
 
130.5 Å, b 
 
5 
 
35.9 Å, c 
 
5 
 
50.5 Å), and contain one
monomer in the asymmetric unit.
 
Data Collection and Structure Solution.
 
X-ray intensity data
were collected at room temperature using a RAXIS IV (Rigaku)
imaging plate system and a Rigaku RU300 rotating anode X-ray
generator equipped with double-focusing mirrors and operating
at 50 kV and 100 mA. Data were processed with BIOTEX (Mo-
lecular Structure Corporation, Inc.). The structure was solved by
molecular replacement (MR) using data from 8.0- to 4.0-Å reso-
lution and the 
 
l
 
1 L chain from antibody HC19 (23), 1GIG, as
the search model. The MR was carried out using EPMR (24),
which resulted in a solution with a correlation coefficient of
0.372. Search models using structures of several antibody H
chains failed to produce a solution. Rigid body refinement of the
L chain using TNT (25), using data from 10.0 to 3.0 Å, reduced
the R factor to 44.6%. Phases from this partial structure were
used to calculate an electron density map that revealed some in-
terpretable density for the H chain. The D1.3 H chain (26),
1VFA, was then manually rotated into the density, and rigid body
refinement was carried out. This reduced the R factor to 35.6%,
at which point the correct side chains were substituted in the H
chain. Positional (xyz) refinement, using data from 10.0 to 2.8 Å,
was then initiated, and reduced the R factor to 22.9%. The re-
sulting electron density map revealed very clear density for the
NPPC hapten, which was then included, and the resulting model
was refined via xyz, and subsequently via positional and thermal
parameter (xyzb) refinement. xyzb refinement was carried out
initially using data from 10.0- to 2.6-Å resolution. The final re-
finement included data extending from 10.0- to 2.35-Å resolu-
tion. The current structure includes residues 1–109 of the L
chain, 1–112 of the H chain, the NPPC molecule, and 88 solvent
molecules. PROCHECK analysis (27) revealed 97.9% of residues
in allowed regions (78% in most favored), and 2.1% in generously
allowed regions. See Table II for selected crystallographic refine-
ment statistics. Coordinates have been deposited in the Protein
Data Bank with accession code 1DL7. 
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Results
 
Affinity of M3C65 Wild-Type and Mutant Antibodies.
 
The M3C65 hybridoma antibody (
 
g
 
2b, 
 
l
 
1) is a member of
a set of clonally related antibodies produced in a secondary
response to PC–protein. High affinity for the hapten ana-
logue NPPC is attributable to mutations at positions 52,
53, and 55 in CDR2 of the 
 
l
 
1 L chain (16). Mutations at
these key positions occur repeatedly in M3C65 clonal rela-
tives, as well as in unrelated 
 
l
 
-bearing anti–PC protein hy-
bridomas, indicating that LCDR2 replacements are vital to
expansion and selection of these memory antibodies (16,
17). To assess whether the hapten–carrier linkage beyond
the diazophenyl moiety forms part of the immunogenic
structure of PC–KLH, we have analyzed binding to a num-
ber of structures representing distinct carrier epitopes. We
also determined whether these structures are recognized
differently as mutations accumulate. A comparison was
made of the affinity of antibody constructs expressing zero
(germline), one, or two mutations with the binding of
M3C65, which contains all three pertinent mutations in
LCDR2. The sequences of the H and L chain V regions
and the positions of mutations are indicated in Fig. 1. The
PC ligands used to measure affinity by fluorescence
quenching are shown in Fig. 2.
Diazophenyl links preferentially to tyrosine or histidine
residues in proteins (28). Because both KLH isoforms con-
tain multiple tyrosine and histidine residues (29), both
amino acids are likely to be haptenated during conjugation
of PC to KLH via a diazophenyl linkage. To analyze the
contribution of a single amino acid linked via diazophenyl
to PC, we compared the affinity for PC–tyrosine or PC–
 
histidine to the affinity for NPPC in antibodies expressing
germline or mutated L chains. As shown in Table I, the rel-
ative affinity for ligand of antibody expressing the unmu-
tated L chain is PC–histidine 
 
$ 
 
PC–tyrosine 
 
. 
 
NPPC,
with the affinity for PC–histidine about ten times that of
the affinity for NPPC. Although the affinity for NPPC in-
creased as mutations accumulated in the L chain, all the
mutant antibodies had higher affinity for PC–tyrosine and
PC–histidine compared with antibody expressing germline
L chain. It is noteworthy that ligand recognition shifts to-
ward PC–tyrosine with the accumulation of mutations in
the M3C65 antibody. Thus, binding to PC–tyrosine or
PC–histidine allows for detection of changes in fine speci-
ficity, with the affinity of the mutated M3C65 antibody for
PC–tyrosine being fivefold greater than for PC–histidine.
These results demonstrate that carrier determinants, as rep-
resented by tyrosine and histidine, contribute to binding,
and that somatic mutation can modulate carrier recognition.
How much of the PC–protein carrier provides determi-
nants recognized by group II antibodies? Previous experi-
ments involving inhibition of binding of M3C65 to PC–
Figure 1. Amino acid sequences of the M3C65 hybridoma antibody
and transfected mutant antibodies. The numbering is according to Kabat
et al. (80). Dashes indicate identity with the germline sequence. The se-
quences of the VH and VL regions of the M3C65 hybridoma are identi-
cal to the sFv fragment expressed in E. coli. (A) Vl1 sequences. There is a
deletion of framework 1 residue 10 in Vl sequences (80), indicated by *.
(B) VH sequences. M3C65 uses the germline PJ14 (Q52 family) and JH3
gene segments (16).
Figure 2. (A) Atom labeling for the hapten NPPC. (B) Chemical
structure of PC ligands used in affinity determinations. The PC–peptide
sequence is Gly-Tyr-Ala with PC coupled to the Tyr residue, or Ser-Asp-
Ala-Leu-Ala-Glu-Met-Tyr-Glu-Leu-Met-Ala-Val-Asp-Gly with PC cou-
pled to the Tyr residue. 
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protein in an ELISA showed that 
 
z
 
10
 
5
 
 times more NPPC
than PC–BSA was required to reduce binding by 50% (16).
Is the superior inhibitory capacity of PC–protein due solely
to the effects of avidity, or does effective binding correlate
with an increase in size of the carrier? To answer these
questions, we determined the intrinsic affinity of antibody
for PC coupled to carriers of varying sizes. The tripeptide
and the 15–amino acid peptide each have only one tyrosine
(and no histidine) in the sequence, and are monosubstituted
with PC (discussed in Materials and Methods), whereas the
histones have multiple tyrosine and histidine residues (30).
The results in Table I show that affinity of antibody ex-
pressing germline 
 
l
 
1 for the PC–GYA tripeptide is higher
than for PC–tyrosine, PC–histidine, or PC–histone. These
findings indicate that neither size nor avidity alone provides
the advantage, but that qualitative characteristics of each in-
dividual carrier can be critical. After the introduction of the
single mutation at position 53, binding to the monosubsti-
tuted 15–amino acid PC–peptide and to PC–histone is at
levels near or equal to the fully mutated antibody. Thus, it
appears that an increase in size of the carrier would benefi-
cially affect binding to germline-encoded antibodies up to a
certain point (PC–GYA 
 
. 
 
PC–histidine 
 
. 
 
NPPC), but a
further increase in size represented by the protein conju-
gate, PC–histone, confers little affinity advantage until mu-
tation occurs.
The cumulative effects of somatic mutation on binding
of small haptens in several systems indicate that high affinity
can result from incremental improvements as mutations ac-
cumulate (31, 32). In M3C65, acquisition of high affinity
for NPPC, PC–tyrosine, or PC–histidine by introduction
of L chain mutations follows a similar pattern (Table I). In
contrast, introduction of a single mutation at LCDR2 posi-
tion 53 accounts for high-affinity binding of the monosub-
stituted 15–amino acid PC–peptide and results in a 200-
fold increase in affinity for PC–histone. Thus, binding to
the haptenic compounds mimics the stepwise acquisition of
high affinity for small haptens seen with other antibodies,
whereas high affinity to the larger PC–carrier structures
may result from a single substitiution. Production of a
high-affinity antibody by a single mutation emphasizes the
adaptive potential of the group II combining site (33). The
surprising difference in the effect of mutation on binding of
the various PC-containing compounds raises a cautionary
note concerning the extrapolation of antihapten binding
results to the in vivo situation, where the complete hapten
conjugate may be the structure relevant to shaping of the
immune repertoire. In addition, as demonstrated here and
by others, somatic mutation not only increases affinity for
hapten, but may also shift antigenic specificity (34–36).
 
Structure Determination and Overall Structure of the M3C65
sFv–NPPC Complex.
 
To determine the molecular basis of
PC–carrier recognition and the contribution of somatic
mutations, the crystal structure of an M3C65 sFv fragment
complexed with NPPC was determined at a resolution of
2.35 Å (atom labeling of NPPC shown in Fig. 2 A). The
sFv fragment of M3C65 was used for crystallographic anal-
ysis because the sFv binding data were in good agreement
with that of intact antibody (Table I). Attempts to analyze
the sFv fragment bound to the higher-affinity ligand, PC–
tyrosine, were unsuccessful because the complex did not
yield data-quality crystals. The crystallographic data collec-
tion and refinement statistics for the sFv–NPPC complex
are shown in Table II.
The combining site of M3C65 is a long narrow groove,
 
z
 
15 Å long by 5 Å wide by 7 Å deep, created by residues
from LCDR1, LCDR2, LCDR3, HCDR2, and HCDR3
(Fig. 3). The binding pocket is unusual in that it is enclosed
at one end by LCDR2 residue Thr55, which seals off the
 
p-
 
nitrophenyl group of the hapten from solvent. Contact
with LCDR2 is rare in antibodies recognizing small hap-
tens (18), but has been seen in the anti-DNP antibody
 
Table I.
 
Binding Constants Determined by Fluorescence Quenching
 
l
 
1 CDR2 residues
Germline
52
N
53
N
55
A NPPC PC–tyrosine PC–histidine
PC–GYA
(3 residues)
PC–peptide
(15 residues) PC–histone
 
K
 
a
 
 
 
3
 
 10
 
6
 
 (M
 
2
 
1
 
)
 
*
 
M3C65 K H T 3.1 (0.2)
 
‡
 
51.1 (0.5) 10.8  (2.8) 5.5  (2.0) 339.2 (72.8) 120.8  (6.0)
MC365 sFv K H T 2.8  (0.2) 53.2 (0.2) 15.0  (0.3) 7.5 (0.5) ND 78.9 (32.7)
Mutants K H – 2.6  (1.0) 38.7 (0.1) 34.5 (13.2) 29.2  (4.9) 373.9 (64.1) 78.9  (5.1)
K–T
 
§
 
0.2 (0.1) 7.5  (0.6) 38.1  (10.3) 10.1 (0.6) ND ND
– H T 0.7  (0.4) 23.2 (5.6) 44.8 (10.2) 37.5 (14.1) ND ND
– H – 0.03 (0.01) 0.2 (0.1) 1.8  (0.1) 3.2  (1.0) 229.6 (30.1) 104.7  (6.0)
Germline – – – 0.03 (0.00) 0.1 (0.03) 0.4  (0.2) 2.9 (0.4) Not detectable 0.5  (0.1)
 
*
 
Affinity constants (K
 
a
 
) were determined by fluorescence quenching at 25
 
8
 
C.
 
‡
 
Values in parentheses are SDs of two to four determinations.
 
§
 
This combination of replacement mutations has not been observed in natural group II hybridomas. 
2105
 
Brown et al.
 
ANO2, which has a similarly shaped combining site (37).
In addition to the steric complementarity of the binding
pocket to the hapten, electrostatic components appear to
be crucial for selective binding and orientation. Specifi-
cally, at one end of the combining site, a negatively
charged patch created by H chain CDR3 residue Asp95 at-
tracts and orients the positively charged trimethylammo-
nium portion of the choline moiety of NPPC (Fig. 3).
 
Antibody–Hapten Interactions.
 
Shape complementarity
and electrostatic contributions anchor NPPC in the bind-
ing site, allowing for optimal interactions with both H and
L chain residues. The absence of water molecules around
the ligand contributes to the tight fit in the binding site,
and calculations using GRASP (38) reveal that NPPC
binding buries 644 Å
 
2
 
 of combining site surface area from
solvent. The contacts from the H chain are provided by
just two residues, HCDR2 residue Trp52 and HCDR3
residue Tyr96 (Table III; Fig. 4). Notably, Tyr96 also
forms part of a “tyrosine sandwich” involving both itself
and LCDR1 residue, Tyr32 (Figs. 3 and 4). These tyrosines
play a critical role in binding by effectively encasing the
central part of the hapten. HCDR2 residues Trp52 and
Met50 combine with residues from LCDR3 (Trp91 and
Trp96) to form a hydrophobic well at the base of the bind-
ing site that interacts with the choline moiety.
Most of the contacts with NPPC involve hypervariable
regions of the M3C65 L chain (Fig. 4; Table III). Asn34
 
from LCDR1 hydrogen bonds to O1 of the phosphate
group of the hapten, whereas Tyr32, the second half of the
“tyrosine sandwich,” encases the phosphate group along
with H chain Tyr96. LCDR3 residues Trp91 and Trp96
interact with the choline moiety, completing the aromatic,
hydrophobic well at the base of the hapten docking site.
There is also a cation-
 
p
 
 interaction between the positively
charged nitrogen of the choline moiety and the indole ring
of Trp96. Cation-
 
p
 
 complexes have been shown to be im-
portant in other biological systems, including a group I
PC-binding antibody M603, where these interactions with
aromatic amino acid side chains enhance recognition of
choline-containing ligands (39).
LCDR2 is the site of the three mutations at positions 52,
53, and 55 that confer increased binding affinity, and the
crystal structure reveals the key roles of His53 and Thr55 in
the formation of the combining site. His53 forms two hy-
drogen bonds, via the side chain N
 
d
 
1, to the carbonyls of L
chain Gly49 (N
 
d
 
1-O, 3.1 Å) and Gly50 (N
 
d
 
1-O, 3.1 Å).
These hydrogen bonds stabilize the combining site and an-
chor the side chain of His53 in a position to stack against
and interact with NPPC. The side chain of His53 directly
 
Table II.
 
Data Collection and Refinement Statistics
 
Resolution range (Å) 10.0–2.35
No. of reflections 8,983
No. of measurements 47,930
Completeness (%) 84
I/(
 
s
 
)I 8.5
Rsym
 
*
 
7.3
Data for highest shell (2.42 to 2.35 Å)
Completeness (%) 47
I/(
 
s
 
)I 1.5
Rsym
 
*
 
26.5
R factor (%)
 
‡
 
19.1
R free (%)
 
§
 
26.5
No. of atoms 1,680
No. of solvent molecules  88
Rms deviations
Bond lengths (Å) 0.014
Bond angles (
 
8
 
) 1.901
B factors (Å
 
2
 
) 3.1
 
*
 
Rsym 
 
5
 
 
 
S/I0, where I0 5 observed intensity and ,I. 5 average in-
tensity obtained from multiple observations of symmetry-related reflec-
tions.
‡R factor 5 SiFobsU 2 UFcalci/SUFobsU. The lower resolution limit of re-
finement for all structures was 10.0 Å.
§R free 5 SiFobsU 2 UFcalci/SUFobsU, where all reflections belong to a test
set of 10% randomly selected data.
Figure 3. The electrostatic surface potential of the M3C65 Fv. Nega-
tive and positive potentials are red and blue, respectively, and neutral ar-
eas are white. The NPPC hapten is colored by atom type with blue nitro-
gen, yellow phosphorus, red oxygen, and white carbon. Positions of the
three CDR2 L chain mutations (K52, H53, and T55) and other amino
acids important in binding NPPC are indicated. The antibody chain des-
ignation, H or L, is in parentheses. The figure was generated using
GRASP (38).2106 Structural Basis of Repertoire Shift
contacts the p-nitrophenyl group of NPPC (Table III), and
also stacks against its aromatic group. The critical role played
by His53 corroborates the finding that CDR2 position 53 is
a specificity-determining residue in l L chains (40).
Residue Thr55 plays two key roles in the architecture of
the binding site near the p-nitrophenyl group. First, this
b-branched residue closes off the end of the binding
groove, allowing a tighter fit with the ligand by exclusion
of water from the site, which is exposed in antibodies using
the germline L chain. Second, Thr55 engages in a hydro-
gen bond from the Od atom to the carbonyl oxygen of
H chain Gly97. This interaction locks the L and H chains
together in the specific conformation required for tight
binding, and is therefore critical. Notably, this interaction is
made possible by the presence of a proline at H chain posi-
tion 98, which has adopted a cis conformation.
The role of mutated residue Lys52 is less clear, as the side
chain is oriented away from the binding pocket. However,
comparison of the M3C65 structure to the germline struc-
ture suggests that the importance of this mutation may lie
in the replacement of the germline asparagine residue. In
the germline l1 structure, Asn52 hydrogen bonds to
Asn53. Such a hydrogen bond would also be possible be-
tween germline Asn52 and the mutated M3C65 His53 side
chain, a contact that would disrupt the crucial contacts pro-
vided by His53. In contrast, a lysine at position 52 would
be unlikely to hydrogen bond to His53, allowing His53 to
make critical architectural contacts necessary for optimal
binding of NPPC. Mutation away from asparagine may be
aided by the high mutability index of the germline codon
sequence (41).
The structural analyses of several other antibody–hapten
interactions indicate that amino acid replacements resulting
from somatic mutation may directly affect contact residues,
but more frequently elicit their effects indirectly via con-
formational changes in the binding site (42–46). However,
in M3C65, both effects are seen. The His53 and Thr55 re-
placements, along with the indirect effects of the Lys52 re-
placement, optimize and fix the shape of the combining
cavity, whereas His53 also contacts the hapten directly.
Comparison of M3C65 l1 Structure with Germline l1.
To assess structural changes in combining site shape result-
ing from somatic mutation, we compared the M3C65 anti-
body with that of an unmutated l1 structure. Superposi-
Figure 4. Stereo top view of the M3C65
combining site complexed with NPPC,
showing residues important for hapten
binding. L chain Gly49 and Gly50 are
shown in the illustration but are not num-
bered. The H chain is on the right in blue,
and the L chain is on the left in pink. Atom
types are indicated by color, with blue ni-
trogen, gold phosphorus, red oxygen, yel-
low sulfur, and white carbon. Dashes indi-
cate hydrogen bonds. The figure was
generated using SYBYL (Tripos, Inc.).
Table III. M3C65 Fv Residues in Contact with NPPC
Segment Residue Fv atom NPPC atom* Distance
Å
VL CDR1 Tyr32 Cd1 C3 3.3
Ce1 C3 3.4
Ce2 O4 3.2
Cd2 O4 2.8
Asn34 Nd2 O1 3.1
CDR2 His53 Ne2 O1N 3.4
CDR3 Trp91 Cd1 C3 3.4
Ce2 C4 3.4
Ch2 C4 3.4
Cz2 C4 3.3
Ne1 C3 3.3
Trp96 Cz2 C2 3.8
VH CDR2 Trp52 Ch2 C4 3.3
CDR3 Tyr96 Cd1 C5A 3.1
Ce1 C5A 3.4
*Labeling of NPPC atoms is shown in Fig. 2 A.2107 Brown et al.
tioning of hybridoma HC19 germline l1 (23) with the
mutated M3C65 sFv shows that the Ca backbone tracings
are quite similar, with a root mean square deviation of 0.50
for 108 corresponding residues (Fig. 5). Strikingly, the only
notable differences between the two structures are observed
in LCDR2 and involve residues 52–56, the region contain-
ing the mutated residues, with the major shifts occurring in
residues Thr55 and Pro56. As noted, this significant shift
results from contacts made by the mutated LCDR2 resi-
dues His53 and Thr55, thus providing the necessary con-
formation of the hapten binding pocket. The Ca backbone
tracings of germline l1 and M3C65 l1 are very similar.
However, one notable shift in amino acid side chain place-
ment occurs in the binding pocket, where L chain residue
Tyr32 has rotated z908 from the germline, orienting the
ring face so that it is more perpendicular to the ligand. This
rotation of Tyr32 also places the Cd of Tyr32 closer to the
O4 of the ligand phosphate group, a shift from 4.0 to 2.8 Å,
such that its positive edge complements the negatively
charged phosphate group. This close approach is indicative
of an unusually strong C-H???O hydrogen bond (47).
Discussion
A shift in antibody repertoire occurs after immunization
with some hapten–protein conjugates, reflecting recruit-
ment of alternative gene combinations at different stages of
the immune response (6). The potential to shift the anti-
body repertoire could play an important role in determin-
ing the ultimate success of immunization, but the molecu-
lar forces driving this complex process are not clear. These
forces are likely to be multifaceted and may include (a) the
precursor frequency of cells expressing a given VH/VL
gene combination (48), (b) intrinsic affinity and/or binding
kinetics of the immunoglobulin B cell receptor for ligand
(3, 6), (c) adaptability of the immunoglobulin receptor to
somatic mutation (8), (d) restrictions in entry into the
memory cell compartment because of differences in B cell
lineage (49), and (e) idiotypic interactions that may down-
regulate dominant clonotypes and promote polyclonality of
the developing memory B cell population (6). In addition,
as discussed here, competitive advantages may lie in the use
of alternative V gene combinations that allow accommoda-
tion of carrier structures, resulting in alteration of initial
patterns of clonal dominance.
Repertoire Shift in the Immune Response to PC–KLH.
Immunization of BALB/c mice with PC–KLH leads to ex-
pression of two antibody populations differing in fine spec-
ificity that predominate in the immune response at differ-
ent times (7, 12–15). This repertoire shift occurs in the late
primary and early secondary response, resulting in loss of
initial dominance by antibodies bearing the T15 idiotype
(group I) and their replacement by group II antibodies that
employ different VH and VL combinations. We propose
that the new gene combinations employed by group II an-
tibodies allow recognition of complex PC–carrier
epitope(s), and that the ability of these combining sites to
be shaped by favorable somatic mutations allows emer-
gence and dominance by group II–specific B cells.
T15 antibodies are restricted to use of the VH1/Vk22 gene
combination. These antibodies undergo little affinity matura-
tion (50–53), and mutated T15 antibodies generally have re-
duced ability to bind antigen (50, 54). It has been suggested
that deleterious mutation of primary antibodies contributes to
loss of dominance in the memory response (55). However,
group II V regions appear to be equally susceptible to harmful
Figure 5. Overlay of the M3C65 V re-
gion (blue) with the germline l1 of anti-
body HC19 (yellow). The orientation of L
chain residue Tyr32 is shown for germline
l1 and M3C65. The positions of mutated
residues 52, 53, and 55 are indicated. The
NPPC hapten (pink) is shown complexed
to M3C65. The figure was generated using
SYBYL (Tripos, Inc.).2108 Structural Basis of Repertoire Shift
mutations (56, 57). Thus, T15 may be unique in the failure of
mutations to improve antigen binding (33).
Group II antibodies use a variety of H and L combi-
nations unrelated to T15 (7). Although the k L chain is
expressed in many memory anti–PC–KLH antibodies,
l-bearing antibodies can dominate (.75%) some responses.
To clarify factors conferring selective advantage to these
antibodies, we focused on the antigen binding properties
and combining site structure of a prototype group II mem-
ory antibody, M3C65. We demonstrate that (a) carrier de-
terminants extending from PC contribute to the affinity of
M3C65, (b) the shape of the M3C65 combining site is well
suited for accommodation of PC in the context of carrier
residues, (c) somatic mutation can alter the specificity for
carrier determinants, and (d) somatic mutation can increase
affinity directly by affecting residues in the combining site
that contact ligand and indirectly by modifying the shape of
the combining site.
More than 35 years ago, it was suggested that antibodies
elicited to conjugated haptens might recognize carrier resi-
dues in addition to the haptenic determinant (58). Defining
the complete antigenic determinant has been difficult, but
in many systems it is thought that the protein carriers of
haptens make a significant contribution to binding by anti-
hapten antibodies (37, 44, 59). However, T15 has approxi-
mately equal intrinsic affinities for PC (Ka 5 2.9 3 105
M21) and NPPC (Ka 5 1.8 3 105 M21), indicating the ab-
sence of a requirement for the diazophenyl linkage be-
tween PC and the protein carrier (60, 61). These results are
in agreement with the earlier conclusion that T15 antibod-
ies recognize only the PC portion of DPPC, another hap-
ten that mimics the linkage between PC and protein (13).
Thus, the carrier linkage does not appear to be an essential
part of the epitope, in contrast to group II antibodies,
where the carrier linkage is an essential feature.
Comparison of Group I and Group II Combining Sites. In-
spection of the binding pockets of two group I antibodies,
T15 (43, 62) and the related antibody M603 (63, 64), re-
veals structural differences that would allow better accom-
modation of carrier residues by group II antibodies. Fig. 6
shows comparative models of T15 bound to PC and
M3C65 bound to NPPC. In the T15 combining site, PC is
bound in a deep pocket anchored by contacts between the
antibody and the phosphate group. The cavity of T15 is
deeper than M3C65 as a result of longer LCDR1,
HCDR2, and HCDR3 loops that protrude farther from
the binding pocket. PC occupies only a small portion of
the combining site, leaving room for carrier residues; how-
ever, the deeper wedge-shaped cavity may hinder accom-
modation of larger carrier structures. Because of the orien-
tation of PC toward the H chain, the HCDR2 region of
T15 would likely interact with carrier epitopes, but the ex-
tended length and protrusion of CDR2 may also restrict
the carrier interactions by steric hindrance. Although rec-
ognition of carrier epitopes can be modulated by mutation
of the T15 HCDR2 loop, the effect on binding is subtle
(65). The shape of the M3C65 binding site appears to be
more suited for binding PC-associated carrier residues than
that of T15, and selected mutations may favor such interac-
tions. The elongated shallow groove of the M3C65 com-
bining site provides a flatter surface more akin to antibodies
recognizing proteins than the deep pockets of many anti-
bodies recognizing small antigens (18, 46, 66). Extension of
carrier residues would continue over the surface of the an-
tibody in such a way as to offer potential interaction with
other residues of LCDR2. The more ideal shape of the
M3C65 binding site for accommodating carrier compared
with T15 is reflected in the 1,000-fold better binding of
PC–protein (7, 16). Thus, the basic geometry of the com-
bining sites differs between these two primary and second-
ary anti-PC antibodies, unlike the response to phenylox-
azolone, where it has been postulated that crucial contact
residues would maintain the same mode of binding after
recruitment of a new VH (67).
Biological Consequences of Repertoire Shift and Somatic Muta-
tion. Repertoire shift is commonly observed during im-
mune responses to hapten conjugates, as well as to viral and
other protein antigens (55, 68–71). Selective pressure on B
cells imposed by affinity for antigen is probably one key
factor influencing the changing antibody repertoire (6). In
the response to PC–protein, recruitment of new gene
combinations produces a corresponding shift away from
recognition of free PC toward higher-affinity recognition
of PC–protein. The affinity of M3C65 for PC–protein (Ka 5
Figure 6. Ribbon diagram showing a
comparison of the combining sites of
M3C65 bound to NPPC (left) and T15
bound to PC (right). The L chain of each
antibody is on the left (blue), and the H
chain is on the right (green). The figure was
generated using SYBYL (Tripos, Inc).2109 Brown et al.
1.2 3108 M21) is in the range for affinities to protein an-
tigens (Ka 5 108–1010 M21) (70, 72, 73), as predicted by
Foote and Eisen (74), and as found for a catalytic antibody
binding to a hapten–peptide conjugate (46). Moreover, the
affinity of the mutated M3C65 for PC–protein is well
above the limit for cellular stimulation (Ka 5 106 M21) de-
termined for a monovalent antigen (75). M3C65 express-
ing germline L chain (Ka 5 0.5 3 106 M21) is just below
this threshold. Presumably, antigen excess and the multiva-
lent nature of PC–KLH allow the repeated selection of
germline-encoded group II antibodies in vivo, whereas the
acquisition of favorable somatic mutations results in expan-
sion of these antibodies. Ka values for the various mutants
are in the range where differences in affinity affect both the
signal transmitted through the B cell receptor and subse-
quent antigen presentation (Ka 5 106–108 M21), but have
not reached the “affinity ceiling” of 1010, beyond which no
further benefit occurs (74, 75).
It has been postulated that repertoire shift could be
driven by kinetic parameters, such that the hydrophobic
and charge characteristics imparted to antibodies by new
VH/VL gene combinations provide high association rates
leading to more efficient long-range attraction of antigen
(3, 76). In addition, a combining site that is more accessible
to antigen can lead to faster binding kinetics (48, 77). It will
be interesting to determine the kinetic rates of the M3C65
mutant antibodies, as well as those of other group II anti-
bodies, for comparison with the T15 antibody. These com-
parisons will allow an evaluation of the effect of combining
site shape and the consequences of somatic mutation on
binding kinetics of antibodies participating in repertoire
shift in the anti–PC–KLH response.
The crystal structure of the M3C65 sFv has allowed us to
correlate binding with structural features of the antibody
that confer advantage to mutated antibodies forming the
group II memory pool. The role of somatic mutation in
optimizing binding site geometry during affinity maturation
has been studied in previous crystallographic analyses of an-
tibody–hapten complexes (44, 67, 78, 79). However, the
structural basis of repertoire shift has remained more elusive
because of the lack of crystal structures representing differ-
ent stages of the maturing antibody response. Comparison
of T15 and M3C65 binding sites illustrates how the accom-
modation of carrier residues provides a mechanism for the
repertoire shift seen in the immune response to PC–KLH.
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